<a href="https://laohu8.com/S/THAR">Tharimmune Inc.</a> Announces $2.5 Million Private Placement to Fund Clinical Development and Working Capital
Tharimmune Inc. has announced a private placement agreement with accredited individual and institutional investors to raise approximately $2.5 million. The company will issue 1,551,351 shares of common stock, pre-funded warrants for 137,838 shares, Series A warrants for 1,689,189 shares at $1.29 per share, and Series B warrants for 844,572 shares at $3.00 per share. The transaction, expected to close on June 20, 2025, pending customary conditions, will see President Street Global acting as the exclusive placement agent. The funds will support Tharimmune's clinical development and working capital needs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-015675), on June 20, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。